Zou Y - Search Results

1

Booser DJ, Perez-Soler R, Cossum P, Esparza-Guerra L, Wu QP, Zou Y, Priebe W, Hortobagyi GN. Booser DJ, et al. Among authors: zou y. Cancer Chemother Pharmacol. 2000;46(5):427-32. doi: 10.1007/s002800000177. Cancer Chemother Pharmacol. 2000. PMID: 11127949

2

Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells.

Ling YH, Zou Y, Priebe W, Perez-Soler R. Ling YH, et al. Among authors: zou y. Int J Cancer. 1995 May 4;61(3):402-8. doi: 10.1002/ijc.2910610321. Int J Cancer. 1995. PMID: 7729954

3

Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes.

Zou Y, Ling YH, Reddy S, Priebe W, Perez-Soler R. Zou Y, et al. Int J Cancer. 1995 May 29;61(5):666-71. doi: 10.1002/ijc.2910610513. Int J Cancer. 1995. PMID: 7768640

4

Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.

Zou Y, Ling YH, Van NT, Priebe W, Perez-Soler R. Zou Y, et al. Cancer Res. 1994 Mar 15;54(6):1479-84. Cancer Res. 1994. PMID: 8137251

5

Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.

Perez-Soler R, Ling YH, Zou Y, Priebe W. Perez-Soler R, et al. Among authors: zou y. Cancer Chemother Pharmacol. 1994;34(2):109-18. doi: 10.1007/BF00685927. Cancer Chemother Pharmacol. 1994. PMID: 8194162

6

Quantitative analysis of the lipophilic doxorubicin analogue annamycin in plasma and tissue samples by reversed-phase chromatography.

Zou Y, Hayman A, Priebe W, Perez-Soler R. Zou Y, et al. J Pharm Sci. 1993 Nov;82(11):1151-4. doi: 10.1002/jps.2600821117. J Pharm Sci. 1993. PMID: 8289131

7

Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles.

Zou Y, Priebe W, Ling YH, Perez-Soler R. Zou Y, et al. Cancer Chemother Pharmacol. 1993;32(3):190-6. doi: 10.1007/BF00685834. Cancer Chemother Pharmacol. 1993. PMID: 8500223

8

Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size.

Zou Y, Priebe W, Perez-Soler R. Zou Y, et al. Cancer Chemother Pharmacol. 1996;39(1-2):103-8. doi: 10.1007/s002800050544. Cancer Chemother Pharmacol. 1996. PMID: 8995506

9

Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.

Perez-Soler R, Neamati N, Zou Y, Schneider E, Doyle LA, Andreeff M, Priebe W, Ling YH. Perez-Soler R, et al. Among authors: zou y. Int J Cancer. 1997 Mar 28;71(1):35-41. doi: 10.1002/(sici)1097-0215(19970328)71:1<35::aid-ijc8>3.0.co;2-4. Int J Cancer. 1997. PMID: 9096663

10

Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity.

Zou Y, Priebe W, Stephens LC, Perez-Soler R. Zou Y, et al. Clin Cancer Res. 1995 Nov;1(11):1369-74. Clin Cancer Res. 1995. PMID: 9815933

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,594 results

Search Page

Filters